ReviewJournal of clinical medicine2019
Hyperprolactinaemia.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Italian Guidelines for the Management of Prolactinomas.Endocrine, metabolic & immune disorders drug targets · 2023Guideline
- Identification of an optimal prolactin threshold to determine prolactinoma size using receiver operating characteristic analysis.Scientific reports · 2021Trial
- Incidence, Treatment Patterns, and Associated Clinical Conditions of Hyperprolactinemia Identified via Nationwide Claims Data in Korea: A 13-Year Population-Based Study.Journal of clinical medicine · 2026Article
- Article
- Article
- Prolactinomas treated with dopaminergic agonists: behavior in different moments of life.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2026Article
- Acromegaly in an elderly male with hepatic malignancy: a case report of a diagnostic dilemma.Annals of medicine and surgery (2012) · 2026Article
- Article
- Mortality in patients with dopamine agonist-treated hyperprolactinemia: a large matched-cohort study.Pituitary · 2025Article
- Sex-specific prolactin disturbance and divergent gonadal hormone correlates in first-episode schizophrenia.The international journal of neuropsychopharmacology · 2025Article
- Mix effect of prolactin on cognitive performance in patients with schizophrenia.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Article
- Recovery of hypopituitarism in macroprolactinomas: a comparison of medical vs. surgical treatment. Results from a European multicenter study.Journal of endocrinological investigation · 2025Article
- Workup of hyperprolactinemia.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Article
- A Narrative Review of Surgery for Prolactinomas: Considerations and Controversies.Journal of clinical medicine · 2025Review
- Severity and influencing factors of hyperprolactinemia in hospitalized schizophrenia patients: a cross-sectional study.Frontiers in psychiatry · 2025Article
- Hormonally Active Pituitary Adenomas and Pregnancy: A Systematic Review.Medical journal of the Islamic Republic of Iran · 2025Review
- Investigating Endocrine Causes in Fluid Non-responsive Hypotension: An Interesting Case of a Pituitary Macroadenoma.Cureus · 2024Article
- Article
- Autoimmune Thyroiditis Mitigates the Effect of Metformin on Plasma Prolactin Concentration in Men with Drug-Induced Hyperprolactinemia.Pharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperprolactinaemia is one of the most common problems in clinical endocrinology. It relates with various aetiologies (physiological, pharmacological, pathological), the clarification of which requires careful history taking and clinical assessment. Analytical issues (presence of macroprolactin or of the hook effect) need to be taken into account when interpreting the prolactin values. Medications and sellar/parasellar masses (prolactin secreting or acting through "stalk effect") are the most common causes of pathological hyperprolactinaemia. Hypogonadism and galactorrhoea are well-recognized manifestations of prolactin excess, although its implications on bone health, metabolism and immune system are also expanding. Treatment mainly aims at restoration and maintenance of normal gonadal function/fertility, and prevention of osteoporosis; further specific management strategies depend on the underlying cause. In this review, we provide an update on the diagnostic and management approaches for the patient with hyperprolactinaemia and on the current data looking at the impact of high prolactin on metabolism, cardiovascular and immune systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.